Companies / BOC Sciences / Mogamulizumab
BOC Sciences

Mogamulizumab | BOC Sciences

(0) Write Review

Mogamulizumab is a monoclonal antibody used in the treatment of certain types of blood cancers, specifically cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Mogamulizumab targets and binds to CC chemokine receptor 4 (CCR4), which is expressed on the surface of malignant T-cells in certain types of lymphomas. By binding to CCR4, mogamulizumab mediates antibody-dependent cellular cytotoxicity (ADCC) and induces apoptosis (programmed cell death) in the cancer cells. It is indicated for the treatment of adult patients with relapsed or refractory CTCL and PTCL. These are types of non-Hodgkin lymphoma that primarily affect T-cells and can present with skin manifestations (in the case of CTCL).

Reviews

(0) | Be the first to review this product
No reviews yet

ABOUT THE COMPANY

BOC Sciences
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
Scientific Products
  • See More
    • Upcoming Virtual Events
    Upcoming Webinars